Trials / Completed
CompletedNCT02211014
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acalabrutinib |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2019-04-26
- Completion
- 2019-04-26
- First posted
- 2014-08-07
- Last updated
- 2020-07-31
- Results posted
- 2020-05-13
Locations
3 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02211014. Inclusion in this directory is not an endorsement.